Related Experiment Video
Updated: Sep 14, 2025
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
15.8K
Emerging Therapeutics for Primary Biliary Cholangitis
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Summary
New treatments for primary biliary cholangitis (PBC) show promise. Selective PPAR agonists and other emerging therapies offer improved options for patients with this autoimmune liver disease, addressing unmet needs beyond ursodeoxycholic acid.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Primary biliary cholangitis (PBC) is an autoimmune liver disease causing progressive bile duct destruction.
- Ursodeoxycholic acid (UDCA) is the standard first-line therapy, but many patients have an inadequate response.
- Existing second-line treatments like obeticholic acid have limitations, including adverse effects.
Purpose of the Study:
- To review recent advances in the treatment of primary biliary cholangitis.
- To highlight novel therapeutic agents and their potential benefits.
- To discuss emerging options for improved patient management.
Main Methods:
- Review of recent clinical trial data for novel PBC therapeutics.
- Analysis of pharmacological targets and mechanisms of action.
- Evaluation of safety and efficacy profiles of new treatment modalities.
Main Results:
- Selective peroxisome proliferator-activated receptor (PPAR) agonists (seladelpar, elafibranor) demonstrate significant efficacy and favorable safety in Phase III trials.
- Emerging therapies targeting symptoms, such as NOX inhibitors and ileal bile acid transporter inhibitors, provide additional management strategies.
- These advancements expand therapeutic options for patients with PBC.
Conclusions:
- Novel agents, particularly PPAR agonists, represent significant progress in PBC treatment.
- Emerging therapeutics offer new hope for managing PBC and its symptoms effectively.
- These advances promise improved outcomes for patients with primary biliary cholangitis.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
01:29Chronic Pancreatitis II: Collaborative Care
128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
128
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
01:17Chronic Bowel Disorders: Introduction
541
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
541
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239